The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index; 8 of the 45 sources its claims cite were checked for support.
Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial
Open accessAbstract
AIM/HYPOTHESIS: To assess whether low-dose glucocorticoid treatment induces adverse metabolic effects, as is evident for high glucocorticoid doses. METHODS: In a randomised placebo-controlled double-blind (participants and the investigators who performed the studies and assessed the outcomes were blinded) dose-response intervention study, 32 healthy men (age 22 ± 3 years; BMI 22.4 ± 1.7 kg/m(2)) were allocated to prednisolone 7.5 mg once daily (n = 12), prednisolone 30 mg once daily (n = 12), or placebo (n = 8) for 2 weeks using block randomisation. Main outcome measures were glucose, lipid and protein metabolism, measured by stable isotopes, before and at 2 weeks of treatment, in the fasted state and during a two-step hyperinsulinaemic clamp conducted in the Clinical Research Unit of the Academic Medical Centre, Amsterdam, the Netherlands RESULTS: Prednisolone, compared with placebo, dose dependently and significantly increased fasting plasma glucose levels, whereas only prednisolone 30 mg increased fasting insulin levels (29 ± 15 pmol/l). Prednisolone 7.5 mg and prednisolone 30 mg decreased the ability of insulin to suppress endogenous glucose production (by 17 ± 6% and 46 ± 7%, respectively, vs placebo). Peripheral glucose uptake was not reduced by prednisolone 7.5 mg, but was decreased by prednisolone 30 mg by 34 ± 6% (p < 0.0001). Compared with placebo, prednisolone treatment tended to decrease lipolysis in the fasted state (p = 0.062), but both prednisolone 7.5 mg and prednisolone 30 mg decreased insulin-mediated suppression of lipolysis by 11 ± 5% and 34 ± 6%, respectively. Finally, prednisolone treatment increased whole-body proteolysis during hyperinsulinaemia, which tended to be driven by prednisolone 30 mg (5 ± 2%; p = 0.06). No side effects were reported by the study participants. All participants completed the study and were analysed. CONCLUSIONS/INTERPRETATION: Not only at high doses but also at low doses, glucocorticoid therapy impaired intermediary metabolism by interfering with the metabolic actions of insulin on liver and adipose tissue. These data indicate that even low-dose glucocorticoids may impair glucose tolerance when administered chronically. TRIAL REGISTRATION: ISRCTN83991850.
Overview
CoChat Summary
TL;DR
In healthy men, 2-week prednisolone treatment at 7.5 mg/day impaired insulin suppression of endogenous glucose production and lipolysis, while 30 mg/day additionally reduced peripheral glucose uptake and increased fasting insulin, glucagon and triglycerides. Low-dose glucocorticoids can induce hepatic and adipose tissue insulin resistance even without changes in body composition.
Key findings
- Prednisolone dose-dependently increased fasting plasma glucose; only prednisolone 30 mg increased fasting insulin levels (29 ± 15 pmol/l) and glucagon, and increased fasting triacylglycerol levels.
- Insulin suppression of endogenous glucose production was impaired by prednisolone 7.5 mg and 30 mg by 17 ± 6% and 46 ± 7%, respectively, vs placebo; peripheral glucose uptake was not reduced by 7.5 mg but was decreased by 30 mg by 34 ± 6% (p < 0.0001).
- Prednisolone tended to decrease fasting lipolysis (p = 0.062) but decreased insulin-mediated suppression of lipolysis by 11 ± 5% (7.5 mg) and 34 ± 6% (30 mg); whole-body proteolysis during hyperinsulinaemia increased overall, tending to be driven by 30 mg (5 ± 2%; p = 0.06).
- Body weight, lean body mass, total fat mass, liver fat content, and visceral/subcutaneous adipose tissue areas were unchanged; all participants completed and were analysed, with one mild gastric discomfort in the 30 mg group and otherwise no treatment-related side effects.
Methods
- Randomised double-blind placebo-controlled dose–response study: 32 healthy white men (age 22 ± 3 years; BMI 22.4 ± 1.7 kg/m²) were allocated to prednisolone 7.5 mg once daily (n = 12), prednisolone 30 mg once daily (n = 12), or placebo (n = 8) for 14 days using block randomisation.
- Glucose, lipid and protein metabolism were measured with stable isotopes ([6,6-²H₂]glucose, [1,1,2,3,3-²H₅]glycerol, L-[1-¹³C]valine) before and at 2 weeks of treatment, in the fasted state and during a two-step hyperinsulinaemic–euglycaemic clamp; body composition was assessed by DEXA, MRI and ¹H-MRS.
- Between-group changes from baseline were tested by Kruskal–Wallis; significant findings were followed by Mann–Whitney U testing with Bonferroni correction, with p < 0.05 considered significant.
Limitations
- Stated: clamp tests were performed under non-steady-state prednisolone levels because prednisolone has a t½ of 4–6 h, so the final part of the clamp may have occurred under lower prednisolone levels; plasma prednisolone may also poorly reflect genomic actions.
- Stated: participants were healthy volunteers, not patients with chronic inflammatory diseases; because systemic inflammation also impairs insulin sensitivity, the combined anti-inflammatory and metabolic effects of glucocorticoids could be more complex in clinical populations.
- Evident: the sample was small (n = 32 total; placebo n = 8), included only healthy white men aged 18–35 with BMI 20–25 kg/m², and treatment lasted only 2 weeks, limiting generalisability to women, older adults, obese or patient populations, and longer-term outcomes.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
7 Valid · 1 Not valid · 20 Not checked · 64 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Insulin-mediated suppression of lipolysis was markedly and dose dependently impaired by prednisolone during hyperinsulinaemic conditions”
§ Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial > Results > Lipid metabolism
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“prednisolone treatment increased proteolysis under hyperinsulinaemic conditions”
§ Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial > Results > Protein metabolism
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fasting EGP was only increased by prednisolone 30 mg (Fig. 1a)”
§ Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial > Results > Glucose metabolism
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Prednisolone treatment did not affect proteolysis in the fasted state”
§ Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial > Results > Protein metabolism
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Prednisolone treatment did not affect the absolute levels of glucose oxidation during hyperinsulinaemia”
§ Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial > Results > Glucose metabolism
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 92 claims and to verify the 2 references still open.
- Probably not a substantial claim. 28
- It may state two separate claims as one. 41
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“due to their effect of increasing basal endogenous glucose production and lowering insulin sensitivity.7–9”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is still unclear if steroid-sparing regimens decrease the risk of PTDM with studies showing mixed results.1591–1595”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1594]
Experimental — accuracy not yet measuredIn the citing paper
“Nevertheless, there is evidence of even low supraphysiological doses of GCs (e.g., prednisolone . mg once daily) impairing glucose tolerance when administered chronically ().”
From Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management (2017) · cites this paper as [199]
In the citing paper
“Prominent hyperglycaemia is most often observed when high dosages of GC are taken by persons with known diabetes, but may also occur at moderate and low doses in persons not previously known to be at risk.3,4”
From Twenty‐four‐hour profiles of plasma glucose, insulin, C‐peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short‐term, medium‐dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action (2012) · cites this paper as [4]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial > Abstract > Results
“No side effects were reported by the study participants.”
§ Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial > Results > Safety and tolerability
“One participant in the prednisolone 30 mg group complained of gastric discomfort which was mild of nature and did not require any intervention.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial > Results > Glucose metabolism
“| Fasting NEFA (nmol/l) | Fasting NEFA (nmol/l) | Fasting NEFA (nmol/l) | Fasting NEFA (nmol/l) | Fasting NEFA (nmol/l) | Fasting NEFA (nmol/l) | | Placebo | 0.5 ± 0.2 | 0.5 ± 0.1 | 0.017 | 1.0 | 0.11 |”
§ Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial > Methods > Glucose, lipid, and valine measurements
“Plasma NEFA concentrations were measured with an enzymatic colorimetric method (NEFA-C test kit; Wako Chemicals, Neuss, Germany) with an intra-assay variation of 1%, inter-assay variation of 4–15% and a detection limit of 0.02 mmol/l.”
Citations
Cites
Calculation of substrate oxidation rates in vivo from gaseous exchange.
Frayn, K. N. (1983) · Journal of Applied Physiology · doi:10.1152/jappl.1983.55.2.628 · Cited by 2,365 · cited 1×
“Glucose oxidation and fatty acid oxidation rates were derived from oxygen consumption and carbon oxide production as reported previously [25].”
MethodINFLUENCES OF GLUCOSE LOADING AND OF INJECTED INSULIN ON HEPATIC GLUCOSE OUTPUT*
Steele, R. (1959) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1959.tb44923.x · Cited by 1,670 · cited 1×
“Calculations Endogenous glucose production (EGP) and the peripheral uptake of glucose (rate of disappearance, Rd) were calculated using modified versions of the Steele equations for the non-steady state and were expressed as μmol kg min as described previously [23, 24].”
MethodPolymyalgia Rheumatica and Giant-Cell Arteritis
Salvarani, C., Cantini, F., Boiardi, L., & Hunder, G. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011913 · Cited by 1,352
Polymyalgia rheumatica and giant-cell arteritis
Salvarani, C., Cantini, F., & Hunder, G. G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61077-6 · Cited by 767
Polymyalgia Rheumatica and Giant Cell Arteritis
Ettlinger, R. E., Hunder, G. G., & Ward, L. E. (1978) · Annual Review of Medicine · doi:10.1146/annurev.me.29.020178.000311 · Cited by 687
Finegood, D. T., Bergman, R. N., & Vranic, M. (1987) · Diabetes · doi:10.2337/diab.36.8.914 · Cited by 546
Buttgereit, F., Da Silva, J. A. P., Boers, M., Burmester, G.-R., Cutolo, M., Jacobs, J., Kirwan, J., Köhler, L., van Riel, P., Vischer, T., et al. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.8.718 · Cited by 544
Glucocorticoids, metabolism and metabolic diseases
Vegiopoulos, A., & Herzig, S. (2007) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2007.05.015 · Cited by 535 · cited 1×
“As such, GCs were shown to induce phosphoenolpyruvate carboxykinase, the rate-controlling enzyme in hepatic glucose production [41].”
BackgroundMechanisms of glucocorticoid-induced myopathy
Schakman, O., Gilson, H., & Thissen, J. P. (2008) · Journal of Endocrinology · doi:10.1677/joe-07-0606 · Cited by 521 · cited 1×
“Moreover, GCs directly activated muscle ring finger-1 and atrogin-1, proteins involved in skeletal muscle proteolysis [43].”
BackgroundGlucocorticoid-induced hyperglycemia
Clore, J. N., & Thurby-Hay, L. (2009) · Endocrine Practice · doi:10.4158/ep08331.rar · Cited by 508
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Lee, M.-J., Pramyothin, P., Karastergiou, K., & Fried, S. K. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.029 · Cited by 380
“Analysis of data from long-term (days to weeks) infusion of GCs [12,114,125,126] is complicated by compensatory hyperinsulinemia whichmay chronically promote higher FA flux via induction of insulin resistance and activation of the sympathetic nervous system.”
BackgroundTreating the Side Effects of Exogenous Glucocorticoids; Can We Separate the Good From the Bad?
Pofi, R., Caratti, G., Ray, D. W., & Tomlinson, J. W. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad016 · Cited by 209
“In a very small study, there is evidence to suggest that even low, supraphysiological doses of GCs (prednisolone 7.5 mg daily) can impair glucose tolerance with prolonged administration (57), although this has not been confirmed in larger cohorts.”
BackgroundInfluentialDiabetes in Cushing syndrome: basic and clinical aspects
Mazziotti, G., Gazzaruso, C., & Giustina, A. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.09.001 · Cited by 193
Isidori, A. M., Graziadio, C., Paragliola, R. M., Cozzolino, A., Ambrogio, A. G., Colao, A., Corsello, S. M., & Pivonello, R. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000415 · Cited by 185
“A randomized controlled trial in humans revealed that glucocorticoids, even at low doses, can increase fasting plasma glucose and insulin levels, and can decrease the ability of insulin to suppress endogenous glucose production and lipolysis, while increasing whole-body proteolysis [73].”
Background
Metadata
- Authors
- van Raalte, D. H., Brands, M., van der Zijl, N. J., Muskiet, M. H., Pouwels, P. J. W., Ackermans, M. T., Sauerwein, H. P., Serlie, M. J., & Diamant, M.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Venue
- Diabetologia
- Published
- 2011-05-12
- Volume
- 54
- Issue
- 8
- Pages
- 2103-2112
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC3131514
- OpenAlex
- W2120890763
- Cited by
- 109
- References
- 52
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 3 · 2023: 6 · 2022: 7 · 2021: 9 · 2020: 7 · 2019: 9 · 2018: 10 · 2017: 1 · 2016: 4 · 2015: 10 · 2014: 5 · 2013: 12 · 2012: 9
- FWCI
- 8.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Diabetologia (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, cc-by-nc)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- Eli Lilly and Company
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Vrije Universiteit Amsterdam
- Novo Nordisk
- Top Institute Pharma
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- prednisolone, low-dose glucocorticoids, intermediary metabolism, glucose metabolism, insulin resistance, lipolysis, hyperinsulinemic-euglycemic clamp, dose-response relationship, prednisolone dose, healthy men, stable isotope tracer infusion, fasting blood glucose, peripheral glucose uptake, lipid metabolism, protein metabolism, metabolic side effects
- MeSH terms
- Adult, Biological Transport, Blood Glucose, Double-Blind Method, Glucocorticoids, Humans, Insulin, Lipolysis, Male, Prednisolone, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. https://app.cochat.ai/papers/10.1007/s00125-011-2174-9
- The paper
- van Raalte, D. H., Brands, M., van der Zijl, N. J., Muskiet, M. H., Pouwels, P. J. W., Ackermans, M. T., Sauerwein, H. P., Serlie, M. J., & Diamant, M. (2011). Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial. Diabetologia. https://doi.org/10.1007/s00125-011-2174-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.